MedTrace Logo

Self Reported Deviations From Opioid Analgesic Prescription

NCT00907192 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 201

Last updated 2013-06-18

No results posted yet for this study

Summary

Primary Objective:

1. To determine the frequency of self-reported over and under use of opioid analgesics in patients with advanced cancer. Patients with advanced cancer are those patients who have been described to have either one of the following: recurrent disease, those that have failed multiple chemotherapies (more than second line therapy), locally advanced disease, and metastatic disease.

Secondary Objectives:

1. To determine the association between patients' knowledge, attitudes and beliefs about opioids, and frequency of deviation in opioid use with patients' demographic information.
2. To determine association between alcohol abuse/chemical coping and self-reported deviations in opioid use.
3. To determine the association between the use of opioids and patient-related barriers to opioid use.

Conditions

Interventions

BEHAVIORAL

Personal Interview

Interview questions about use of pain drugs and other knowledge and/or attitudes about them. Take about 5-10 minutes to complete.

BEHAVIORAL

Questionnaire

5 short questionnaires about use of pain drugs, attitudes about the pain drugs and their use, and concerns about use of these pain drugs. Take about 10-15 minutes to complete.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Eduardo Bruera, MD · UT MD Anderson Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00907192 on ClinicalTrials.gov